TABLE 2

Treatment, clinical, and biochemical parameters of type B insulin-resistant patients during therapy

Patient	Time from diagnosis (months)	BMI (kg/m²)	Fasting blood glucose (mg/dl)	Fasting plasma insulin (pmol/l)	A1C (%)	Leptin (μg/l)	Adiponectin (mg/l)*	Diabetes treatment	Immunosuppression	Anti-insulin receptor antibody titer	Serum creatinine (mg/dl)/CrCL (ml/min)†
1	0	20.4	244	11952	10.2	<0.1	51.1	Metformin, 4,000 IU insulin/day	Nil	+++	0.4/149
	6	21.8	66	17682	8.6	1.2	21.9	2,350 IU insulin/day	Nil	++	0.3/152
	11	23.4	78	11681	8.7	2.3	16.3	1,250 IU insulin/day	Nil	+	0.4/157
	17	23.8	55	14015	8	9.8	15.6	1,250 IU insulin/day	Nil	–	0.4/143
	35	30.1	81	82	5.7	55.7	6.2	Nil	Nil	–	0.6/113
2	0	19.1	85	490	5.1	35.6	42	Rosiglitazone, metformin, 450 IU insulin/day	60 mg prednisone/day	+++	0.5/152
	3	21.8	70	212	7.6	18.6	60	Rosiglitazone, metformin, 450 IU insulin/day	5 mg prednisone/day	+	0.5/134
3	0	23	378	6876	8.7	6	31.3	1,000 IU insulin/day	Plasmapheresis, rituximab, and cyclophosphamide	+++	0.5/NA
	10	24.9	69	249	7.3	48.4	21.8	Nil	20 mg prednisone/day	+	0.7/166
4	0	31.1	237	17029	12.1	<0.1	54.2	1,400 IU insulin/day	Nil	+++	0.6/NA
5	0	25.6	108	2979	8.4	8.5	36.2	1,200 IU insulin/day	20 mg prednisone/day	++	1.4/76
6	0	16.8	63	12,500	12.1	0.4	32.0	2,800 IU insulin/day	Nil	++	0.3/NA
7	0	20.7	321	42852	11.9	1.7	54.4	19,000 IU insulin/day	Nil	+++	0.6/97

Reference ranges for leptin and adiponectin are the 5th–95th percentiles from sex- and BMI-matched nondiabetic controls.
*
* Normal ranges for adiponectin from a control population of 515 healthy control women are 4.4–17.7 mg/l for BMI <25 kg/m², 3.5–15.5 mg/l for BMI 25–30 kg/m², and 2.6–14.9 mg/l for BMI 30–35 kg/m².
†
† CrCL, creatinine clearance, determined from 24-h urine collection.